For rheumatoid arthritis, they are not replacements for your DMARD or biologic but the 2025 research from centers like UCLA suggests they can be a powerful complement: less disease activity, fewer flares, lower inflammation markers, better cholesterol and blood sugar, and reduced cardiovascular risk sometimes even at low doses
Travelling with an injectable IMP such as retatrutide requires advance planning and written confirmation of requirements from the trial site
Researchers meta-analyzed 20 large published randomized controlled studies with 83,288 patients and found a very small but not statistically significant increase in NAION in those treated with GLP-1s
The TODAY (Treatment Options for Type 2 Diabetes in Adolescents and Youth) study showed that 60.1% of young T2D patients had at least one micro-vascular complication after an average follow-up of 13.3 years, with 28.4% having at least two complications [3]
Online accounted for a significant market share in 2023, and Hospital Pharmacies is expected to hold a dominant position in the forecast period owing to as it plays a critical role in ensuring that patients receiving inpatient care or undergoing medical procedures have uninterrupted access to GLP-1 receptor agonists